Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3912 + fulvestrant ± TQB3616 in HR+/HER2- breast cancer
NCT06851442Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tqb3912 in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose, Phase II Recommended Dose and 1 more. Started May 2025; status: terminated.
02
Drugs
tqb3912
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06851442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851442.